GSK, iTeos TIGIT drug belrestotug shows efficacy in PD-L1-high NSCLC trial at ESMO, giving some positive news for the beleaguered class.

The demise of iTeos Therapeutics-partnered TIGIT inhibitor belrestotug does not come as a complete surprise, given the well-documented challenges faced by companies developing this class of drug ...

Find the latest iTeos Therapeutics, Inc. (ITOS) stock quote, history, news and other vital information to help you with your stock trading and investing.

A deal to acquire Alkermes spinout Mural Oncology is Xoma’s fourth since June and the latest evidence of interest in buying ...

Under the terms of the proposed transaction, Concentra will acquire iTeos for $10.047 in cash per share, plus one non-transferable contingent value right, representing the right to receive: (i ...

A high-level overview of Keros Therapeutics, Inc. (KROS) stock. View (KROS) real-time stock price, chart, news, analysis, analyst reviews and more.

Use our Earnings Calendar to track forecasts for quarterly and annual earnings reports as well as actual outcomes from companies worldwide.

Get the latest news and real-time alerts from Enanta Pharmaceuticals, Inc. (ENTA) stock at Seeking Alpha.

Find the latest Zymeworks Inc. (ZYME) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.

Xoma, a drug royalty specialist, buys another ‘zombie’ biotech A deal to acquire Alkermes spinout Mural Oncology is Xoma’s fourth since June and is the latest evidence of interest in buying and ...